Your browser doesn't support javascript.
loading
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Bellmunt, J; Mullane, S A; Werner, L; Fay, A P; Callea, M; Leow, J J; Taplin, M E; Choueiri, T K; Hodi, F S; Freeman, G J; Signoretti, S.
Affiliation
  • Bellmunt J; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston; Medical Oncology Department, Brigham and Women's Hospital, Boston; Medical Oncology Department, Harvard Medical School, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston. Electronic address: joaquim_bellmunt@dfci.ha
  • Mullane SA; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston.
  • Werner L; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston.
  • Fay AP; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston.
  • Callea M; Department of Pathology, Brigham and Women's Hospital, Boston.
  • Leow JJ; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston.
  • Taplin ME; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston; Medical Oncology Department, Brigham and Women's Hospital, Boston; Medical Oncology Department, Harvard Medical School, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston.
  • Choueiri TK; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston; Medical Oncology Department, Brigham and Women's Hospital, Boston; Medical Oncology Department, Harvard Medical School, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston.
  • Hodi FS; Medical Oncology Department, Harvard Medical School, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston; Center for Immuno-oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Freeman GJ; Medical Oncology Department, Harvard Medical School, Boston; Medical Oncology Department, Dana-Farber Cancer Institute, Boston.
  • Signoretti S; Bladder Cancer Center, Dana-Farber Cancer Institute, Boston; Medical Oncology Department, Harvard Medical School, Boston; Department of Pathology, Brigham and Women's Hospital, Boston.
Ann Oncol ; 26(4): 812-817, 2015 Apr.
Article de En | MEDLINE | ID: mdl-25600565
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome transitionnel / Marqueurs biologiques tumoraux / Lymphocytes TIL / Tumeurs urologiques / Antigène CD274 Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Animals / Humans Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2015 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome transitionnel / Marqueurs biologiques tumoraux / Lymphocytes TIL / Tumeurs urologiques / Antigène CD274 Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Animals / Humans Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2015 Type de document: Article Pays de publication: Royaume-Uni